Topical and light-based treatments for basal cell carcinoma.
Nonsurgical methods of treatment providing cure rates approaching those provided by surgery offer a significant advantage to patients with basal cell carcinoma (BCC) in certain anatomic locations. While intralesional interferon has been used to treat BCC with some success, the deliver method requires multiple visits to the doctor's office, which makes compliance a challenge for the patient. Initial success with light-based therapy of BCC over a decade ago has not evolved to the point where it is an effective, widely available treatment. The new class of immune response modifiers, represented by topical imiquimod cream, shows promise for providing topical treatment of early BCC. It is hoped that further developments of the class of drugs will produce an agent with fewer side effects and improved efficacy for nodular BCC.
Robinson
June K
JK
Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA. jrobin5@lumc.edu
Hernandez
Claudia
C
Anderson
E Ratcliffe
ER
Nickoloff
Brian
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007167:Immunotherapy / Q000379:methods; D007372:Interferons / Q000008:administration & dosage*; D053685:Laser Therapy / Q000379:methods; D010778:Photochemotherapy / Q000379:methods*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007372:Interferons; D000077271:Imiquimod